Introduction Methods
Identification of studies Diabetic nephropathy is a leading cause of end-stage renal failure in the Western world, and the number of Studies with a case-control and/or cross-sectional diabetic patients needing dialysis or kidney trans-design were considered, without language limitations, plantation is increasing steadily [1] . While the possibil-provided that they were published as original articles. ities for treatment of these patients have improved All studies were included which contained sufficient substantially by introduction of antihypertensive information to allow a comparison of ACE/ID therapy and, perhaps particularly, angiotensin-genotype distributions between adult cases (with converting enzyme (ACE) inhibitors, our knowledge IDDM/NIDDM and elevated urinary albumin excreof the mechanisms involved in the development of this tion rate, as defined by the authors) and diabetic devastating microvascular complication is still sparse. controls without an elevated urinary albumin excretion Studies of familial clustering [2] [3] [4] and genetic pre-rate. Where studies on the same cases and control disposition [5, 6 ] suggest that genetic factors are subjects had been reported more than once, only one involved in the pathogenesis of diabetic nephropathy. study was included. Abstracts were excluded and One candidate gene is the gene coding for ACE in unpublished studies were not sought. which an insertion/deletion polymorphism (ACE/ID) Studies were identified by an electronic search has been described [7] . Based on the presence [insertion performed on Current Contents and MEDLINE (I )] or absence [deletion (D)] of a 287 bp sequence in (1993-1997) using the search terms: angiotensinintron 16, three genotypes are found (DD and II converting enzyme gene and diabetes. The last elechomozygotes and ID heterozygotes). The DD subjects tronic search was conducted on November 24, 1997. (diabetic [8, 9] or non-diabetic [7] ) are characterized Further studies were sought by reading through the by a mean plasma/serum ACE level approximately reference lists of the identified studies. double that of II subjects, with ID subjects having intermediate values. Furthermore, this polymorphism has been associated with an increased risk of coronary Statistical analysis heart disease both in non-diabetic [10] and diabetic populations [11, 12] .
The following items were extracted from the included In diabetes, the initial report from Marre et al. [8] studies: number of cases and controls, ethnic backproposed a protective effect of the II genotype against ground, criteria and methods for classification of cases development of diabetic nephropathy in insulin-and controls, ACE/ID genotype frequencies and duradependent diabetes (IDDM ). Since then, a substantial tion of diabetes. Before data analysis, it was decided number of association studies have been conducted to to analyse IDDM and NIDDM studies separately and investigate the possible relationships between elevated to stratify analyses further according to ethnic backurinary albumin excretion rate and the ACE/ID poly-ground, since ACE/ID genotype distribution varies morphism in patients with either IDDM or non-considerably with race [13, 14] . insulin-dependent diabetes (NIDDM ). The aim of this Funnel plots comparing sample size with the odds review is to evaluate the prevalence of ACE/ID geno-ratio of individual studies were drawn to estimate the types in diabetic patients with and without an elevated risk of publication bias. If no publication bias exists, urinary albumin excretion rate.
the points scatter around the pooled value of the odds ratio, with the scatter narrowing as sample size increases. The linear regression approach was used to intercept from regression of odds ratio/standard error size. The linear regression analysis revealed no significant funnel plot asymmetry in either IDDM patients against precision (1/standard error) [15] .
Depending on the absence or presence of study [intercept (90% CI ) −1. Figure 2 . The pooled odds ratio across all studies in IDDM patients is 0.72 (0.51-1.01), P=0.06. In Caucasian NIDDM patients, the corresponding value Eleven studies including IDDM patients satisfied the is 0.86 (0.68-1.10), P=0.23, and in Japanese NIDDM specified criteria and were included [8, 9, 13, [19] [20] [21] [22] [23] [24] [25] [26] .
patients it is 0.50 (0.37-0.69), P<0.0001. When anaPredominantly Caucasians were included: only 10 of lyses were conducted by calculating odds ratios for 494 patients in one of the French reports [24] were DD vs ID+II genotypes, the pooled odds ratio for non-Caucasians, while ethnicity was not accounted for IDDM patients was 1.12 (0.95-1.32), for Caucasian in a British study (n=104) [20] . Table 1 [22, [27] [28] [29] [30] and five studies were based on Japanese populations [14, [31] [32] [33] [34] . A total of 730 cases Discussion and 836 controls were included in the Caucasian part ( Table 2) , while 478 cases and 284 controls were Japanese ( Table 3 ). The genotype frequencies of all The magnitude of the literature published on diabetic nephropathy and ACE/ID polymorphism has been control populations were in Hardy-Weinberg equilibrium.
increasing steadily since Marre et al. [8] published their initial report on the topic in 1994. Out of 11 Figure 1 is the funnel plot of the estimate of the log odds ratio for II vs DD+ID genotype against sample reports in IDDM, only two French reports [8, 24] and a small Russian study [26 ] have found a significant nephropathy and the ACE/ID polymorphism could be demonstrated. In the second publication from Marre association between the ACE/ID polymorphism and an elevated urinary albumin excretion rate to be et al. [24] , a subgroup of cases all had persistent macroalbuminuria; a reduced proportion of these present. In NIDDM, none of the five studies in Caucasians, but three [14, 32, 33] out of five studies in patients had the II genotype.
Major differences with respect to type and interval Japanese patients demonstrated a positive association.
The results of the different studies have been of urine collections and determination of urinary albumin concentration/excretion rate may contribute to the conflicting for a number of reasons: the phenotypic characterization of cases and controls is rather observed heterogeneity between studies: some investigators rely on the less accurate qualitative urine stix heterogenous and a variety of selection criteria have been applied.
[21,25], some use timed urine collections, while others base their classification of patients on spot-urine Criteria for the diagnosis of diabetic kidney disease differ substantially between studies. The majority of samples only [20, 21, 25, 28, [32] [33] [34] . Some investigators require several urine samples for their classification of studies include patients with both micro-and macroalbuminuria among cases, despite the knowledge that cases, others settle for one [14, 19, 26, 30] . Finally, some investigators [28] have defined new cut-offs, differing not all IDDM patients with microalbuminuria will progress to macroalbuminuria and some might even from established criteria [36 ] , for classification of patients as micro-and macroalbuminuric, respectively. regress to normoalbuminuria [35] ; nor in NIDDM patients does microalbuminuria always lead to overt In some studies [22] , inclusion of patients with elevated urinary albumin excretion rate but without diabetic diabetic nephropathy and the associated decline in kidney function [35] . Only four studies of IDDM retinopathy will allow a number of patients with nondiabetic kidney or urinary tract diseases to be included patients [9, 21, 25, 26 ] and three NIDDM studies [14, 30, 31] have included cases with macroalbuminuria among cases.
Selection of controls is another contributor to the exclusively. Except in three relatively small studies [14, 26, 30] , no overall association between overt variation between studies. With respect to phenotype, genotype [38] [39] [40] , who furthermore have an increased risk of coronary heart disease [11, 12] . Such a poor prognosis could lead to a selective loss of nephropathic patients homozygous for the D allele.
In an attempt to avoid duplicated data, data from the initial report from Schmidt et al. [13] dealing with NIDDM patients is not included here, since the second publication [29] is clearly an expansion of the original cohort. The potential overlap of patients in the two reports from Marre et al. [8, 24] is not accounted for in their second publication, but since inclusion of patients in this latter study was not initiated until after publication of the first paper, data from both reports have been included in this review.
Publication bias leading to earlier and more frequent publication of studies reporting positive results is well known in the medical literature. To avoid premature publication of positive findings, interim findings were not included in the present analysis. Furthermore, testing the funnel plots by a regression analysis only revealed significant asymmetry within the group of studies dealing with ACE/ID polymorphism and diabetic nephropathy in Caucasian NIDDM patients. Thus, publication bias does not appear to be a major problem in this analysis.
Two previous meta-analyses [41, 42] of various cardiovascular-renal disorders and the ACE/ID polymorphism have proposed the D allele to be associated with increased risk of diabetic nephropathy in general. Their conclusions are based on a rather heterogenous selection of studies of Caucasian and non-Caucasian patients with IDDM and NIDDM and varying levels of urinary albumin excretion rate. The present analysis suggests that the association between the ACE/ID populations (n=762) and that the impact in Caucasian Caucasian NIDDM and (C ) Japanese NIDDM patients. An estimate of the log odds ratio for the II genotype vs ID+DD genotypes IDDM patients (n=2688) is less, although there was combined against sample size for each study is shown. The horizontal a similar tendency. Since the ACE/ID polymorphism lines indicate the pooled estimates. If no publication bias exists the is probably only a marker for the functional polypoints scatter around the pooled value of the odds ratio, with the scatter narrowing as sample size increases.
morphism that influences ACE levels [7] , the degree of disequilibrium between the two may vary from population to population and thus contribute to the observed discrepancy between populations. some studies [21, 30, 31] actually include patients with Thus, within the limitations of available data, this microalbuminuria in the control group; others overview suggests that the ACE/ID polymorphism [20, 22, 27, 33, 34] have chosen their controls with a contributes to the genetic susceptibility to diabetic relatively short duration of diabetes, and thus cannot nephropathy in Japanese NIDDM patients, but does exclude that some of their controls will eventually not play a major role in the initiation of diabetic develop diabetic nephropathy [37] . Finally, a variety nephropathy in Caucasian NIDDM patients. In of different inclusion and exclusion criteria have been Caucasian IDDM patients, comparison of data is applied, i.e. a requirement for the presence of prolifercomplicated by differences between study populations, ative retinopathy in the study by Marre et al. [24] or but a trend towards a protective effect of the II exclusion of normotensive cases [21] or patients treated genotype on the development of increased urinary with ACE inhibitors [14, 32] .
albumin excretion rate was observed. Introduction of selection bias to association studies Furthermore, several studies have suggested the is a major problem, created not only by investigators, ACE/ID polymorphism to play an important role as but possibly also by nature. In the current field, several a progression promoter in diabetic nephropathy reports have suggested an increased rate of progression of diabetic kidney disease in patients carrying the DD [38-40]. in non-insulin-dependent diabetes mellitus. Nephron 1995; 70:
